Laboratory of Connective Tissue Pathology, Research Institute of Clinical and Experimental Lymphology - Branch of the Federal Research Center Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia.
Bull Exp Biol Med. 2024 Apr;176(6):786-790. doi: 10.1007/s10517-024-06109-9. Epub 2024 Jun 19.
The COVID-19 pandemic has brought significant changes in managing of patients with rheumatoid arthritis. Rituximab-treated patients were more susceptible to severe infection. This required a "switch" to another genetically engineered drug in the patients with high risk of adverse COVID-19. In this study, we assessed the severity of immune response to SARS-CoV-2 antigens in rituximab-treated patients with rheumatoid arthritis vaccinated with the combined vector vaccine Gam-COVID-Vac. Insufficient formation of the humoral response and a high level of T-cell response to SARS-CoV-2 antigens in this group of patients were revealed. An imbalance of cellular and humoral response may play a role in more severe COVID-19 in rituximab-treated patients with rheumatoid arthritis.
COVID-19 大流行给类风湿关节炎患者的管理带来了重大变化。接受利妥昔单抗治疗的患者更容易发生严重感染。这要求在 COVID-19 不良风险高的患者中“切换”另一种基因工程药物。在这项研究中，我们评估了接受联合载体疫苗 Gam-COVID-Vac 接种的类风湿关节炎利妥昔单抗治疗患者对 SARS-CoV-2 抗原的免疫反应严重程度。结果显示，该组患者对 SARS-CoV-2 抗原的体液反应不足，T 细胞反应水平较高。细胞和体液反应的失衡可能在接受利妥昔单抗治疗的类风湿关节炎患者中导致更严重的 COVID-19。
